Kronvall Erik, Sayer Faisal T, Nilsson Ola G
Neurokirurgiska kliniken, Universitetssjukhuset i Lund.
Lakartidningen. 2005;102(24-25):1887-8, 1890.
Methylprednisolone (MP) has, through the results from the clinical multi-center studies National Acute Spinal Cord Injury Study II and III, during the 1990's become standard treatment in acute spinal cord injury (ASCI). Critical reappraisals of the data have later shown that analyses have been made on subgroups of the study-populations and argue that the results are based on statistical artefacts. This, combined with the failure to show improved functional recovery, puts into question earlier conclusions drawn on the efficacy of MP on ASCI. This review of the recent literature on the subject concludes that there is no scientific evidence to support MP as standard treatment in ASCI.
通过20世纪90年代全国急性脊髓损伤研究II和III的临床多中心研究结果，甲基强的松龙（MP）已成为急性脊髓损伤（ASCI）的标准治疗方法。后来对数据的严格重新评估表明，是对研究人群的亚组进行了分析，并认为结果是基于统计假象。这一点，再加上未能显示出功能恢复得到改善，使得早期关于MP对ASCI疗效得出的结论受到质疑。对该主题近期文献的综述得出结论，没有科学证据支持MP作为ASCI的标准治疗方法。
